Kornhuber J, Riederer P, Reynolds G P, Beckmann H, Jellinger K, Gabriel E
Department of Psychiatry, University of Würzburg, Federal Republic of Germany.
J Neural Transm. 1989;75(1):1-10. doi: 10.1007/BF01250639.
In post-mortem putamen samples from 27 schizophrenics and 27 controls D2 receptors were measured by Scatchard analysis using 3H-spiperone as a ligand. Maximum number of binding sites (Bmax) and apparent dissociation constant (KD) were significantly increased only in patients in whom neuroleptic medication had been given within a three-month period before death. When the neuroleptic medication had been withdrawn at least 3 month before death, there was a slight, but not significant, reduction in Bmax values and unchanged KD values. Withdrawal of neuroleptic drugs was followed by a normalization of the KD values within 2 weeks and a slower reduction of Bmax values. There were 6 schizophrenic patients with mainly positive schizophrenic symptoms and 17 patients with mainly negative symptoms; positive schizophrenic symptoms were not related to higher Bmax values. There was no difference in 3H-spiperone binding between patients with and without movement disorders (tardive dyskinesia or extrapyramidal symptoms).
在取自27名精神分裂症患者和27名对照者的尸检壳核样本中，以3H-螺哌隆作为配体，通过Scatchard分析测定D2受体。仅在死亡前三个月内接受过抗精神病药物治疗的患者中，结合位点的最大数量（Bmax）和表观解离常数（KD）显著增加。当抗精神病药物在死亡前至少3个月停用后，Bmax值略有降低，但不显著，KD值未改变。停用抗精神病药物后，KD值在2周内恢复正常，Bmax值下降较慢。有6名主要表现为阳性精神分裂症症状的精神分裂症患者和17名主要表现为阴性症状的患者；阳性精神分裂症症状与较高的Bmax值无关。有运动障碍（迟发性运动障碍或锥体外系症状）和无运动障碍的患者之间，3H-螺哌隆结合无差异。
